{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:06:13Z","timestamp":1789722373281,"version":"4.0.1"},"reference-count":254,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.addr.2025.115671","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T02:00:04Z","timestamp":1754618404000},"page":"115671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Classic versus innovative strategies for immuno-therapy in pancreatic cancer"],"prefix":"10.1016","volume":"225","author":[{"given":"Maria Giovanna","family":"Formelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Palloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Tavolari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Deiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Andrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lamberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2025.115671_b0005","unstructured":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries - PubMed."},{"issue":"4","key":"10.1016\/j.addr.2025.115671_b0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated Projection of US Cancer Incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"6","key":"10.1016\/j.addr.2025.115671_b0015","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41392-021-00659-4","article-title":"The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives","volume":"5","author":"Wang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.addr.2025.115671_b0020","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/SLA.0000000000004147","article-title":"Actual Five-year Survival after Upfront Resection for Pancreatic Ductal Adenocarcinoma: who Beats the odds?","volume":"275","author":"Strobel","year":"2022","journal-title":"Ann. Surg."},{"key":"10.1016\/j.addr.2025.115671_b0025","unstructured":"Cancer of the Pancreas - Cancer Stat Facts. SEER."},{"issue":"18","key":"10.1016\/j.addr.2025.115671_b0030","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.addr.2025.115671_b0035","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.addr.2025.115671_b0040","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.3390\/curroncol29100541","article-title":"The Role of Immunotherapy in Pancreatic Cancer","volume":"29","author":"Mukherji","year":"2022","journal-title":"Curr. Oncol."},{"issue":"16","key":"10.1016\/j.addr.2025.115671_b0045","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance","volume":"24","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"issue":"4","key":"10.1016\/j.addr.2025.115671_b0050","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"6332","key":"10.1016\/j.addr.2025.115671_b0055","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1\u2013mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.addr.2025.115671_b0060","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001901","article-title":"Considerations for treatment duration in responders to immune checkpoint inhibitors","volume":"9","author":"Marron","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.addr.2025.115671_b0065","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in patients with Noncolorectal High Microsatellite Instability\/Mismatch Repair\u2013Deficient Cancer: results from the phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.addr.2025.115671_b0075","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1634\/theoncologist.2016-0046","article-title":"Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade","volume":"21","author":"Lee","year":"2016","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.addr.2025.115671_b0080","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","article-title":"Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities","volume":"35","author":"Wang","year":"2024","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.addr.2025.115671_b0085","first-page":"1729","article-title":"Pasca di Magliano M, Maitra a","volume":"186","author":"Halbrook","year":"2023","journal-title":"Pancreatic Cancer: Advances and Challenges. Cell."},{"issue":"4","key":"10.1016\/j.addr.2025.115671_b0090","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.3390\/cancers15041235","article-title":"Hypoxia, a Targetable Culprit to Counter Pancreatic Cancer Resistance to Therapy","volume":"15","author":"Abou Khouzam","year":"2023","journal-title":"Cancers"},{"issue":"22","key":"10.1016\/j.addr.2025.115671_b0095","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1200\/JCO.2010.28.1386","article-title":"Gemcitabine Plus Bevacizumab Compared with Gemcitabine Plus Placebo in patients with Advanced Pancreatic Cancer: phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)","volume":"28","author":"Kindler","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.addr.2025.115671_b0100","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1200\/JCO.2008.20.0238","article-title":"Phase III Trial of Bevacizumab in Combination with Gemcitabine and Erlotinib in patients with Metastatic Pancreatic Cancer","volume":"27","author":"Van Cutsem","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.addr.2025.115671_b0105","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"issue":"14","key":"10.1016\/j.addr.2025.115671_b0110","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1158\/0008-5472.CAN-23-2352","article-title":"Multiplexed Imaging Mass Cytometry Analysis Characterizes the Vascular Niche in Pancreatic Cancer","volume":"84","author":"Sussman","year":"2024","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.addr.2025.115671_b0115","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","article-title":"Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy","volume":"55","author":"Choi","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"46","key":"10.1016\/j.addr.2025.115671_b0120","doi-asserted-by":"crossref","first-page":"18632","DOI":"10.1073\/pnas.1318415110","article-title":"Combining two strategies to improve perfusion and drug delivery in solid tumors","volume":"110","author":"Stylianopoulos","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.addr.2025.115671_b0125","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.18632\/oncotarget.2948","article-title":"Inhibition of HIF-1\u03b1 by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma","volume":"6","author":"Zhao","year":"2014","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.addr.2025.115671_b0130","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3390\/cancers14051302","article-title":"Is Sphingosine-1-Phosphate a Regulator of Tumor Vascular Functionality?","volume":"14","author":"Karam","year":"2022","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.addr.2025.115671_b0135","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1002\/ijc.28597","article-title":"Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy","volume":"134","author":"Raykov","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.addr.2025.115671_b0140","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.ijrobp.2021.02.012","article-title":"Tumor Oxygenation by Myo-Inositol Trispyrophosphate Enhances Radiation Response","volume":"110","author":"Grgic","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0145","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1038\/s41467-021-24069-w","article-title":"Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors","volume":"12","author":"Schneider","year":"2021","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.addr.2025.115671_b0150","first-page":"259","article-title":"Oxygen microcapsules improve immune checkpoint blockade by ameliorating hypoxia condition in pancreatic ductal adenocarcinoma","volume":"1","author":"Wu","year":"2023","journal-title":"Bioact. Mater."},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0155","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12885-023-10829-y","article-title":"Phase I\/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol)","volume":"23","author":"Thivat","year":"2023","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.addr.2025.115671_b0160","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1016\/j.ijrobp.2022.07.1097","article-title":"Quantifying Gadolinium-based, Theranostic Nanoparticle Uptake in MR Images of Pancreatic Cancer","volume":"114","author":"Bennett","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"10","key":"10.1016\/j.addr.2025.115671_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-022-05351-1","article-title":"Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.addr.2025.115671_b0170","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"172","key":"10.1016\/j.addr.2025.115671_b0175","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.addr.2021.02.012","article-title":"Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts","volume":"1","author":"Liu","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.addr.2025.115671_b0180","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.3390\/cancers15092614","article-title":"A Quick Guide to CAF Subtypes in Pancreatic Cancer","volume":"15","author":"Brichkina","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0185","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","article-title":"Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer","volume":"62","author":"Jacobetz","year":"2013","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.addr.2025.115671_b0190","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"issue":"27","key":"10.1016\/j.addr.2025.115671_b0195","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III Trial of Pegvorhyaluronidase Alfa with Nab-Paclitaxel Plus Gemcitabine for patients with Hyaluronan-High Metastatic Pancreatic Adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.addr.2025.115671_b0200","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1200\/JCO.18.01295","article-title":"Phase IB\/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in patients with Metastatic Pancreatic Adenocarcinoma: SWOG S1313","volume":"37","author":"Ramanathan","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.addr.2025.115671_b0205","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003254","article-title":"VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects","volume":"9","author":"Bazan-Peregrino","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0210","article-title":"Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine","volume":"6","author":"Nagaraju","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"23","key":"10.1016\/j.addr.2025.115671_b0215","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1158\/1078-0432.CCR-23-1405","article-title":"A pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU\/LV in Advanced Pancreatic Cancer patients after Progression on Gemcitabine-based Therapy","volume":"29","author":"Grierson","year":"2023","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res."},{"issue":"78","key":"10.1016\/j.addr.2025.115671_b0220","article-title":"Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy","volume":"19","author":"Yang","year":"2022","journal-title":"EBioMedicine"},{"issue":"22","key":"10.1016\/j.addr.2025.115671_b0225","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12943-023-01813-y","article-title":"Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma","volume":"24","author":"Gautam","year":"2023","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.addr.2025.115671_b0230","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3390\/ijms20030676","article-title":"Inflammation and Pancreatic Cancer: Focus on Metabolism, Cytokines, and Immunity","volume":"20","author":"Padoan","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.addr.2025.115671_b0235","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccr.2012.04.024","article-title":"Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia","volume":"21","author":"Pylayeva-Gupta","year":"2012","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.addr.2025.115671_b0240","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2012.04.025","article-title":"Tumor-derived granulocyte-macrophage colony stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer","volume":"21","author":"Bayne","year":"2012","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.addr.2025.115671_b0245","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/cgt.2016.65","article-title":"Myeloid-derived suppressor cells and their role in pancreatic cancer","volume":"24","author":"Pergamo","year":"2017","journal-title":"Cancer Gene Ther."},{"issue":"24","key":"10.1016\/j.addr.2025.115671_b0250","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.21.02616","article-title":"Immunologic strategies in Pancreatic Cancer: making Cold Tumors Hot","volume":"40","author":"Ullman","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115671_b0255","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.3389\/fimmu.2019.03070","article-title":"Deciphering the Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma","volume":"10","author":"Siret","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2025.115671_b0260","doi-asserted-by":"crossref","unstructured":"Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med. 2014 May 21;6(237):237ra67.","DOI":"10.1126\/scitranslmed.3007974"},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0265","first-page":"62","article-title":"Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1\/CXCR2 results in antitumor immunity and durable response in pancreatic cancer","volume":"4","author":"Gulhati","year":"2023","journal-title":"Nat Cancer."},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0270","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.addr.2025.115671_b0275","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ccell.2018.10.006","article-title":"RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer","volume":"34","author":"Wang","year":"2018","journal-title":"Cancer Cell"},{"issue":"268","key":"10.1016\/j.addr.2025.115671_b0280","article-title":"Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment","volume":"1","author":"Zhou","year":"2021","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.addr.2025.115671_b0285","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1053\/j.gastro.2022.02.024","article-title":"Stromal HIF2 Regulates Immune suppression in the Pancreatic Cancer Microenvironment","volume":"162","author":"Garcia Garcia","year":"2022","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.addr.2025.115671_b0290","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccell.2016.09.011","article-title":"Characteristics and significance of the Pre-metastatic Niche","volume":"30","author":"Liu","year":"2016","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.addr.2025.115671_b0295","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nri3789","article-title":"Immune cell promotion of metastasis","volume":"15","author":"Kitamura","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.addr.2025.115671_b0300","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5858\/133.3.413","article-title":"The Pathology and Genetics of Metastatic Pancreatic Cancer","volume":"133","author":"Yachida","year":"2009","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"10","key":"10.1016\/j.addr.2025.115671_b0305","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.3748\/wjg.v23.i10.1872","article-title":"Prognostic value of site-specific metastases in pancreatic adenocarcinoma: a Surveillance Epidemiology and end results database analysis","volume":"23","author":"Oweira","year":"2017","journal-title":"World J. Gastroenterol."},{"issue":"7806","key":"10.1016\/j.addr.2025.115671_b0310","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.addr.2025.115671_b0315","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.molimm.2013.11.020","article-title":"Blocking oncogenic RAS enhances tumour cell surface MHC class I expression but does not alter susceptibility to cytotoxic lymphocytes","volume":"58","author":"El-Jawhari","year":"2014","journal-title":"Mol. Immunol."},{"issue":"6282","key":"10.1016\/j.addr.2025.115671_b0320","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.aac9935","article-title":"MYC Regulates the Anti-Tumor Immune Response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.addr.2025.115671_b0325","doi-asserted-by":"crossref","unstructured":"Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U. c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. Mod Pathol Off J U S Can Acad Pathol Inc. 2002 Apr;15(4):462\u20139.","DOI":"10.1038\/modpathol.3880547"},{"issue":"13","key":"10.1016\/j.addr.2025.115671_b0330","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.3390\/cancers13133119","article-title":"Tumor Mutational Burden as a potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open questions","volume":"13","author":"Lawlor","year":"2021","journal-title":"Cancers"},{"issue":"1\u20132","key":"10.1016\/j.addr.2025.115671_b0335","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","article-title":"EMT and dissemination precede pancreatic tumor formation","volume":"148","author":"Rhim","year":"2012","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.addr.2025.115671_b0340","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for locally Advanced or Metastatic Pancreatic Adenocarcinoma","volume":"33","author":"Royal","year":"1997","journal-title":"J Immunother Hagerstown Md"},{"key":"10.1016\/j.addr.2025.115671_b0345","article-title":"Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma","volume":"36(4_suppl):470\u2013470","author":"Sharma","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.addr.2025.115671_b0350","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of Anti\u2013PD-L1 Antibody in patients with Advanced Cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.addr.2025.115671_b0355","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without Tremelimumab for patients with Metastatic Pancreatic Ductal Adenocarcinoma","volume":"5","author":"O\u2019Reilly","year":"2019","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.addr.2025.115671_b0360","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/annonc\/mdu205","article-title":"A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer","volume":"25","author":"Aglietta","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.addr.2025.115671_b0365","doi-asserted-by":"crossref","unstructured":"Kalyan A, Kircher SM, Mohindra NA, Nimeiri HS, Maurer V, Rademaker A, et al. Ipilimumab and gemcitabine for advanced pancreas cancer: A phase Ib study . J Clin Oncol. 2016 May 20;34(15_suppl):e15747\u2013e15747.","DOI":"10.1200\/JCO.2016.34.15_suppl.e15747"},{"issue":"5","key":"10.1016\/j.addr.2025.115671_b0370","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1634\/theoncologist.2019-0473","article-title":"Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: a phase Ib Study","volume":"25","author":"Kamath","year":"2020","journal-title":"Oncologist"},{"issue":"18","key":"10.1016\/j.addr.2025.115671_b0375","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-0099","article-title":"Open-label, phase I Study of Nivolumab combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer","volume":"26","author":"Wainberg","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0380","first-page":"1","article-title":"Spatial interactions of immune cells as potential predictors to efficacy of toripalimab plus chemotherapy in locally advanced or metastatic pancreatic ductal adenocarcinoma: a phase Ib\/II trial","volume":"9","author":"Cheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0385","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10637-017-0525-1","article-title":"Phase Ib\/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma","volume":"36","author":"Weiss","year":"2018","journal-title":"Invest. New Drugs"},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s44276-023-00028-4","article-title":"A phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer","volume":"2","author":"Morizane","year":"2024","journal-title":"BJC Rep."},{"issue":"13","key":"10.1016\/j.addr.2025.115671_b0395","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1038\/s41467-022-32591-8","article-title":"The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma","volume":"26","author":"Renouf","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115671_b0400","doi-asserted-by":"crossref","unstructured":"Gang J, Guo S, Zhang Y, Ma Y, Guo X, Zhou X, et al. A phase II study of KN046 monotherapy as 2nd line and above treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2022 Jun;40(16_suppl):e16305\u2013e16305.","DOI":"10.1200\/JCO.2022.40.16_suppl.e16305"},{"key":"10.1016\/j.addr.2025.115671_b0405","doi-asserted-by":"crossref","unstructured":"Jin G, Guo S, Zhang Y, Ma Y, Guo X, Zhou X, et al. Efficacy and safety of KN046 plus nab-paclitaxel\/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). J Clin Oncol. 2021 May 20;39(15_suppl):4138\u20134138.","DOI":"10.1200\/JCO.2021.39.15_suppl.4138"},{"key":"10.1016\/j.addr.2025.115671_b0410","doi-asserted-by":"crossref","unstructured":"Jin G, Guo S, Xu J, Liu R, Liang Q, Yang Y, et al. A multicenter, randomized, double-blind phase III clinical study to evaluate the efficacy and safety of KN046 combined with nab-paclitaxel and gemcitabine versus placebo combined with nab-paclitaxel and gemcitabine in patients with advanced pancreatic cancer (ENREACH-PDAC-01). J Clin Oncol. 2022 Jun 1;40(16_suppl):TPS4189\u2013TPS4189.","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4189"},{"issue":"Suppl 3","key":"10.1016\/j.addr.2025.115671_b0415","article-title":"New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40\/TNFR5)","volume":"4","author":"Piechutta","year":"2019","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.addr.2025.115671_b0420","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.addr.2025.115671_b0425","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1053\/j.gastro.2013.07.025","article-title":"Activated Pancreatic Stellate Cells Sequester CD8+ T-Cells to Reduce their Infiltration of the Juxtatumoral Compartment of Pancreatic Ductal Adenocarcinoma","volume":"145","author":"Ene-Obong","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.addr.2025.115671_b0430","doi-asserted-by":"crossref","unstructured":"Fan J qiao, Wang MF, Chen HL, Shang D, Das JK, Song J. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Mol Cancer. 2020 Feb 15;19:32.","DOI":"10.1186\/s12943-020-01151-3"},{"issue":"13","key":"10.1016\/j.addr.2025.115671_b0435","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1158\/1078-0432.CCR-19-0081","article-title":"Mobilization of CD8+ T cells via CXCR4 blockade facilitates PD-1 checkpoint therapy in human pancreatic cancer","volume":"25","author":"Seo","year":"2019","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res."},{"issue":"6","key":"10.1016\/j.addr.2025.115671_b0440","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/s41591-020-0880-x","article-title":"BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial","volume":"26","author":"Bockorny","year":"2020","journal-title":"Nat. Med."},{"issue":"10018","key":"10.1016\/j.addr.2025.115671_b0445","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet Lond Engl."},{"issue":"5","key":"10.1016\/j.addr.2025.115671_b0450","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","article-title":"Targeting FAK in anticancer combination therapies","volume":"21","author":"Dawson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"24","key":"10.1016\/j.addr.2025.115671_b0455","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1158\/1078-0432.CCR-22-0308","article-title":"Defactinib, Pembrolizumab, and Gemcitabine in patients with Advanced Treatment Refractory Pancreatic Cancer: a phase I Dose Escalation and expansion Study","volume":"28","author":"Wang-Gillam","year":"2022","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res."},{"key":"10.1016\/j.addr.2025.115671_b0460","doi-asserted-by":"crossref","unstructured":"Lim KH, Spencer KR, Safyan RA, Picozzi VJ, Varghese AM, Siolas D, et al. Avutometinib\/defactinib and gemcitabine\/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b\/2 study (RAMP 205). J Clin Oncol. 2024 Jun;42(16_suppl):4140\u20134140.","DOI":"10.1200\/JCO.2024.42.16_suppl.4140"},{"issue":"3","key":"10.1016\/j.addr.2025.115671_b0465","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-15-0827","article-title":"Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer","volume":"6","author":"Gunderson","year":"2016","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0470","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000587","article-title":"Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer","volume":"8","author":"Overman","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.addr.2025.115671_b0475","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000500571","article-title":"A phase 1b\/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in patients with Pretreated Solid Tumors","volume":"97","author":"Hong","year":"2019","journal-title":"Oncol Switz."},{"key":"10.1016\/j.addr.2025.115671_b0480","article-title":"Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: results from the phase 2a study","volume":"1","author":"Naing","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.addr.2025.115671_b0485","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2217\/fon-2020-0215","article-title":"Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication","volume":"16","author":"Lamberti","year":"2020","journal-title":"Future Oncol Lond Engl."},{"issue":"8","key":"10.1016\/j.addr.2025.115671_b0490","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(22)00369-2","article-title":"A Randomized phase Ib\/II Study of Niraparib plus Nivolumab or Ipilimumab in patients with Platinum-Sensitive Advanced Pancreatic Cancer","volume":"23","author":"Reiss","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.addr.2025.115671_b0495","doi-asserted-by":"crossref","unstructured":"Zhen DB, Whittle M, Ritch PS, Hochster HS, Coveler AL, George B, et al. Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic adenocarcinoma (mPC): PCRT16-001. J Clin Oncol. 2022 Jan 5;40(4_suppl):576\u2013576.","DOI":"10.1200\/JCO.2022.40.4_suppl.576"},{"key":"10.1016\/j.addr.2025.115671_b0500","doi-asserted-by":"crossref","unstructured":"Algaze S, Hanna DL, Azad NS, Thomas JS, Iqbal S, Habib D, et al. A phase Ib study of guadecitabine and durvalumab in patients with advanced hepatocellular carcinoma, pancreatic adenocarcinoma, and biliary cancers. J Clin Oncol. 2022 Feb 1;40(4_suppl):574\u2013574.","DOI":"10.1200\/JCO.2022.40.4_suppl.574"},{"issue":"2","key":"10.1016\/j.addr.2025.115671_b0505","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/2159-8290.CD-18-0710","article-title":"IL1-Induced JAK\/STAT Signaling is Antagonized by TGF\u03b2 to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma","volume":"9","author":"Biffi","year":"2019","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.addr.2025.115671_b0510","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s43018-021-00269-7","article-title":"Radiation Therapy Enhances Immunotherapy Response in Microsatellite-stable Colorectal and Pancreatic Adenocarcinoma in a phase II Trial","volume":"2","author":"Parikh","year":"2021","journal-title":"Nat Cancer."},{"key":"10.1016\/j.addr.2025.115671_b0515","article-title":"Randomized phase II Study of Nivolumab with or without Ipilimumab combined with Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC)","volume":"20","author":"Chen","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.addr.2025.115671_b0520","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1158\/1078-0432.CCR-19-3624","article-title":"Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in patients with Metastatic Pancreatic Ductal Adenocarcinoma","volume":"26","author":"Xie","year":"2020","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res."},{"issue":"180","key":"10.1016\/j.addr.2025.115671_b0525","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2022.11.035","article-title":"Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R)","volume":"1990","author":"Chen","year":"2023","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"209","key":"10.1016\/j.addr.2025.115671_b0530","article-title":"Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials","volume":"1","author":"Lynch","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.addr.2025.115671_b0535","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005292","article-title":"Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy","volume":"10","author":"Dercle","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0540","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s43088-025-00610-4","article-title":"Advancing pancreatic cancer management: the role of artificial intelligence in diagnosis and therapy","volume":"14","author":"Ozsahin","year":"2025","journal-title":"Beni-Suef Univ J Basic Appl Sci."},{"issue":"3","key":"10.1016\/j.addr.2025.115671_b0545","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/jmri.27871","article-title":"Preoperative Radiomics Approach to evaluating Tumor-Infiltrating CD8+ T Cells in patients with Pancreatic Ductal Adenocarcinoma using Noncontrast magnetic Resonance Imaging","volume":"55","author":"Bian","year":"2022","journal-title":"J. Magn. Reson. Imaging"},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0550","doi-asserted-by":"crossref","first-page":"6695","DOI":"10.1038\/s41467-023-42453-6","article-title":"Validation of MSIntuit as an AI-based pre-screening tool for MSI detection from colorectal cancer histology slides","volume":"14","author":"Saillard","year":"2023","journal-title":"Nat. Commun."},{"issue":"10409","key":"10.1016\/j.addr.2025.115671_b0555","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet Lond Engl."},{"issue":"7","key":"10.1016\/j.addr.2025.115671_b0560","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/cas.15377","article-title":"Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs","volume":"113","author":"Milano","year":"2022","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0565","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/s12951-023-02083-y","article-title":"Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy","volume":"21","author":"Kiaie","year":"2023","journal-title":"J Nanobiotechnology."},{"issue":"51","key":"10.1016\/j.addr.2025.115671_b0570","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202303261","article-title":"Lipid Nanoparticle (LNP) Enables mRNA delivery for Cancer Therapy","volume":"35","author":"Zong","year":"2023","journal-title":"Adv. Mater."},{"issue":"5","key":"10.1016\/j.addr.2025.115671_b0575","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"issue":"10","key":"10.1016\/j.addr.2025.115671_b0580","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.3390\/pharmaceutics14102225","article-title":"Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA delivery for Effective Gene Silencing in Triple-negative Breast Cancer Cells","volume":"14","author":"Camorani","year":"2022","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.addr.2025.115671_b0585","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2217\/nnm-2018-0237","article-title":"Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes","volume":"14","author":"Wu","year":"2019","journal-title":"Nanomed"},{"issue":"33","key":"10.1016\/j.addr.2025.115671_b0590","doi-asserted-by":"crossref","first-page":"6805","DOI":"10.1039\/C5TB00912J","article-title":"Preparation of optimized lipid-coated calcium phosphate nanoparticles for enhanced in vitro gene delivery to breast cancer cells","volume":"3","author":"Tang","year":"2015","journal-title":"J. Mater. Chem. B Mater. Biol. Med."},{"issue":"6","key":"10.1016\/j.addr.2025.115671_b0595","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1021\/acsnano.6b08152","article-title":"Dual Targeting Nanoparticle Stimulates the Immune System to Inhibit Tumor Growth","volume":"11","author":"Kosmides","year":"2017","journal-title":"ACS Nano"},{"issue":"7","key":"10.1016\/j.addr.2025.115671_b0600","article-title":"Codelivery of Anti-PD-1 Antibody and Paclitaxel with Matrix Metalloproteinase and pH Dual-Sensitive Micelles for Enhanced Tumor Chemoimmunotherapy","volume":"16","author":"Su","year":"2020","journal-title":"Small Weinh Bergstr Ger."},{"key":"10.1016\/j.addr.2025.115671_b0605","doi-asserted-by":"crossref","unstructured":"Wan W jun, Qu C xi, Zhou Y juan, Zhang L, Chen M tian, Liu Y, et al. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy. Int J Pharm. 2019 Jul 20;566:731\u201344.","DOI":"10.1016\/j.ijpharm.2019.06.030"},{"issue":"9","key":"10.1016\/j.addr.2025.115671_b0610","doi-asserted-by":"crossref","first-page":"8690","DOI":"10.1021\/acsnano.7b01786","article-title":"Transient and Local Expression of Chemokine and Immune Checkpoint Traps to Treat Pancreatic Cancer","volume":"11","author":"Miao","year":"2017","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.addr.2025.115671_b0615","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1148\/radiol.2017162759","article-title":"Ten things you Might not know about Iron Oxide Nanoparticles","volume":"284","author":"Daldrup-Link","year":"2017","journal-title":"Radiology"},{"issue":"14","key":"10.1016\/j.addr.2025.115671_b0620","doi-asserted-by":"crossref","first-page":"6278","DOI":"10.7150\/thno.42564","article-title":"Multifunctional magnetic iron oxide nanoparticles: an advanced platform for cancer theranostics","volume":"10","author":"Zhao","year":"2020","journal-title":"Theranostics"},{"issue":"138","key":"10.1016\/j.addr.2025.115671_b0625","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.addr.2019.01.005","article-title":"Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications","volume":"1","author":"Dadfar","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.addr.2025.115671_b0630","doi-asserted-by":"crossref","first-page":"579","DOI":"10.7150\/thno.48811","article-title":"MRI-traceable theranostic nanoparticles for targeted cancer treatment","volume":"11","author":"Anani","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0635","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1038\/s41467-020-17380-5","article-title":"Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy","volume":"11","author":"Yu","year":"2020","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.addr.2025.115671_b0640","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/nnano.2016.168","article-title":"Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues","volume":"11","author":"Zanganeh","year":"2016","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.addr.2025.115671_b0645","doi-asserted-by":"crossref","unstructured":"Ruiz-de-Angulo A, Bilbao-Asensio M, Cronin J, Evans SJ, Clift MJD, Llop J, et al. Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis. iScience. 2020 Sep 25;23(9):101499.","DOI":"10.1016\/j.isci.2020.101499"},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0650","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202001451","article-title":"Advances in magnetic Nanoparticle-Mediated Cancer Immune-Theranostics","volume":"10","author":"Cheng","year":"2021","journal-title":"Adv. Healthc. Mater."},{"issue":"12","key":"10.1016\/j.addr.2025.115671_b0655","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1515\/nanoph-2021-0196","article-title":"Fe2P nanorods based photothermal therapy combined with immune checkpoint inhibitors for pancreatic cancer","volume":"10","author":"Liu","year":"2021","journal-title":"Nanophotonics"},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0660","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1021\/acsnano.9b08550","article-title":"Combined magnetic Hyperthermia and Immune Therapy for Primary and Metastatic Tumor Treatments","volume":"14","author":"Pan","year":"2020","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.addr.2025.115671_b0665","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ijc.34195","article-title":"Exploring the potential of exosomes in diagnosis and drug delivery for pancreatic ductal adenocarcinoma","volume":"152","author":"Xu","year":"2023","journal-title":"Int. J. Cancer"},{"issue":"7659","key":"10.1016\/j.addr.2025.115671_b0670","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/nature22341","article-title":"Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer","volume":"546","author":"Kamerkar","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0675","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1039\/C9NR05865F","article-title":"SPION decorated exosome delivery of TNF-\u03b1 to cancer cell membranes through magnetism","volume":"12","author":"Zhuang","year":"2019","journal-title":"Nanoscale"},{"issue":"24","key":"10.1016\/j.addr.2025.115671_b0680","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1158\/1078-0432.CCR-10-0978","article-title":"Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal gold-rhTNF Nanomedicine","volume":"16","author":"Libutti","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115671_b0685","doi-asserted-by":"crossref","unstructured":"Sandin LC, Eriksson ,Fredrik, Ellmark ,Peter, Loskog ,Angelica SI, T\u00f6tterman ,Thomas H, and Mangsbo SM. Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. OncoImmunology. 2014 Jan 1;3(1):e27614.","DOI":"10.4161\/onci.27614"},{"issue":"373","key":"10.1016\/j.addr.2025.115671_b0690","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jconrel.2024.07.023","article-title":"Enhancing pancreatic cancer immunotherapy: Leveraging localized delivery strategies through the use of implantable devices and scaffolds","volume":"1","author":"Minaei","year":"2024","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.addr.2025.115671_b0695","first-page":"12","article-title":"Hydrogel systems for spatiotemporal controlled delivery of immunomodulators: engineering the tumor immune microenvironment for enhanced cancer immunotherapy","volume":"13","author":"Liu","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0700","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nbt.3071","article-title":"Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy","volume":"33","author":"Kim","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0705","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12951-024-02646-7","article-title":"Injectable hybrid hydrogels enable enhanced combination chemotherapy and roused anti-tumor immunity in the synergistic treatment of pancreatic ductal adenocarcinoma","volume":"22","author":"Zhou","year":"2024","journal-title":"J Nanobiotechnology."},{"issue":"9","key":"10.1016\/j.addr.2025.115671_b0710","article-title":"Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer","volume":"10","author":"Liu","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.addr.2025.115671_b0715","doi-asserted-by":"crossref","unstructured":"Wang C, Wang J, Zhang X, Yu S, Wen D, Hu Q, et al. In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. Sci Transl Med. 2018 Feb 21;10(429):eaan3682.","DOI":"10.1126\/scitranslmed.aan3682"},{"issue":"20","key":"10.1016\/j.addr.2025.115671_b0720","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202203264","article-title":"In Situ formed ROS-Responsive Hydrogel with STING Agonist and Gemcitabine to Intensify Immunotherapy against Pancreatic Ductal Adenocarcinoma","volume":"12","author":"Wang","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.addr.2025.115671_b0725","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122453","article-title":"Dual-crosslinking immunostimulatory hydrogel synchronously suppresses pancreatic fistula and pancreatic cancer relapse post-resection","volume":"305","author":"Zhao","year":"2024","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.addr.2025.115671_b0730","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S1470-2045(24)00079-2","article-title":"LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1\/2 study","volume":"25","author":"Musher","year":"2024","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.addr.2025.115671_b0735","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002723","article-title":"Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead","volume":"9","author":"Kirtane","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0740","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/jso.24627","article-title":"CAR T-cell Therapy for Pancreatic Cancer","volume":"116","author":"Delm","year":"2017","journal-title":"J. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.addr.2025.115671_b0745","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor (CAR) design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"issue":"22","key":"10.1016\/j.addr.2025.115671_b0750","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0755","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.addr.2025.115671_b0760","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1172\/JCI80010","article-title":"CAR therapy: the CD19 paradigm","volume":"125","author":"Sadelain","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.addr.2025.115671_b0765","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-Targeted CARs: Driving T cells to Solid Tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0770","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","article-title":"Activity of Mesothelin-specific Chimeric Antigen Receptor T cells against Pancreatic Carcinoma Metastases in a phase 1 Trial","volume":"155","author":"Beatty","year":"2018","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.addr.2025.115671_b0775","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.addr.2025.115671_b0780","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.ymthe.2020.07.017","article-title":"Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in patients with Metastatic Pancreatic Cancer","volume":"28","author":"Ko","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2025.115671_b0785","unstructured":"University of Pennsylvania. Phase I Study of Human Chimeric Antigen Receptor Modified T Cells (CAR T Cells) in Patients With Pancreatic Cancer. clinicaltrials.gov; 2024 Oct. Report No.: NCT03323944."},{"issue":"7","key":"10.1016\/j.addr.2025.115671_b0790","first-page":"1252","article-title":"Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma. World J Gastrointest","volume":"14","author":"Wang","year":"2022","journal-title":"Oncol"},{"key":"10.1016\/j.addr.2025.115671_b0795","first-page":"13","article-title":"Claudin and pancreatic cancer. Front","volume":"7","author":"Wang","year":"2023","journal-title":"Oncol"},{"issue":"7","key":"10.1016\/j.addr.2025.115671_b0800","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/14737140.2024.2357802","article-title":"The trend toward more target therapy in pancreatic ductal adenocarcinoma","volume":"24","author":"Deiana","year":"2024","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.addr.2025.115671_b0805","article-title":"Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2\u2013positive metastatic pancreatic cancer (mPC): phase 2, open-label, randomized study","volume":"41(4_suppl):TPS782\u2013TPS782","author":"Park","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0810","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-023-01491-9","article-title":"CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer","volume":"16","author":"Qi","year":"2023","journal-title":"J Hematol OncolJ Hematol Oncol."},{"issue":"3","key":"10.1016\/j.addr.2025.115671_b0815","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/0008-5472.CAN-06-2030","article-title":"Identification of Pancreatic Cancer Stem Cells","volume":"67","author":"Li","year":"2007","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.addr.2025.115671_b0820","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1053\/j.gastro.2012.07.017","article-title":"Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice","volume":"143","author":"Maliar","year":"2012","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.addr.2025.115671_b0825","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s13238-017-0440-4","article-title":"Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers","volume":"9","author":"Feng","year":"2018","journal-title":"Protein Cell"},{"issue":"7","key":"10.1016\/j.addr.2025.115671_b0830","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0835","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/00006676-200407000-00061","article-title":"The Correlation between Cytoplasmic Overexpression of Epidermal Growth factor Receptor and Tumor Aggressiveness: Poor Prognosis in patients with Pancreatic Ductal Adenocarcinoma","volume":"29","author":"Ueda","year":"2004","journal-title":"Pancreas"},{"issue":"10","key":"10.1016\/j.addr.2025.115671_b0840","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jcyt.2020.04.088","article-title":"Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: a phase I clinical trial","volume":"22","author":"Liu","year":"2020","journal-title":"Cytotherapy"},{"key":"10.1016\/j.addr.2025.115671_b0845","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pharmthera.2016.06.010","article-title":"Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps","volume":"166","author":"Beatty","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"17","key":"10.1016\/j.addr.2025.115671_b0850","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.omto.2020.05.009","article-title":"Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1\/PD-L1 for Treating Pancreatic Cancer","volume":"26","author":"Yang","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"issue":"6","key":"10.1016\/j.addr.2025.115671_b0855","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1172\/JCI87624","article-title":"Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors","volume":"127","author":"Smith","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.addr.2025.115671_b0860","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1021\/acscentsci.2c00163","article-title":"Bioorthogonal Equipping CAR-T Cells with Hyaluronidase and Checkpoint Blocking Antibody for Enhanced Solid Tumor Immunotherapy","volume":"8","author":"Zhao","year":"2022","journal-title":"ACS Cent. Sci."},{"issue":"11","key":"10.1016\/j.addr.2025.115671_b0865","doi-asserted-by":"crossref","first-page":"10724","DOI":"10.1021\/acsnano.7b04955","article-title":"Biomimetic Magnetosomes as Versatile Artificial Antigen-Presenting Cells to Potentiate T-Cell-Based Anticancer Therapy","volume":"11","author":"Zhang","year":"2017","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.addr.2025.115671_b0870","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12875","article-title":"Development of tumour peptide vaccines: from universalization to personalization","volume":"91","author":"Ma","year":"2020","journal-title":"Scand. J. Immunol."},{"issue":"7","key":"10.1016\/j.addr.2025.115671_b0875","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2326-6066.CIR-14-0027","article-title":"Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation","volume":"2","author":"Lutz","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"14","key":"10.1016\/j.addr.2025.115671_b0880","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1038\/s41467-023-39196-9","article-title":"A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma","volume":"20","author":"Heumann","year":"2023","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.addr.2025.115671_b0885","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.ccell.2022.10.001","article-title":"Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"issue":"499","key":"10.1016\/j.addr.2025.115671_b0890","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.canlet.2020.11.041","article-title":"CD137 Agonist-based Combination Immunotherapy Enhances Activated, Effector memory T cells and Prolongs Survival in Pancreatic Adenocarcinoma","volume":"28","author":"Muth","year":"2021","journal-title":"Cancer Lett."},{"issue":"25","key":"10.1016\/j.addr.2025.115671_b0895","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2025.115671_b0900","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.biomaterials.2016.09.031","article-title":"Exosome-based tumor antigens-adjuvant co-delivery utilizing genetically engineered tumor cell-derived exosomes with immunostimulatory CpG DNA","volume":"111","author":"Morishita","year":"2016","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2025.115671_b0905","doi-asserted-by":"crossref","unstructured":"Xiao L, Erb ,Ulrike, Zhao ,Kun, Hackert ,Thilo, and Z\u00f6ller M. Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer. OncoImmunology. 2017 Jun 3;6(6):e1319044.","DOI":"10.1080\/2162402X.2017.1319044"},{"issue":"7963","key":"10.1016\/j.addr.2025.115671_b0910","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115671_b0915","first-page":"1","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"19","author":"Sethna","year":"2025","journal-title":"Nature"},{"issue":"232","key":"10.1016\/j.addr.2025.115671_b0920","article-title":"Breakthroughs in nanoparticle-based strategies for pancreatic cancer therapy","volume":"1","author":"Escalera-Anzola","year":"2025","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.addr.2025.115671_b0925","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.actbio.2014.09.020","article-title":"Degradable polymer-coated gold nanoparticles for co-delivery of DNA and siRNA","volume":"1","author":"Bishop","year":"2015","journal-title":"Acta Biomater."},{"issue":"2","key":"10.1016\/j.addr.2025.115671_b0930","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003928","article-title":"Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches","volume":"10","author":"Won","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0935","doi-asserted-by":"crossref","first-page":"11335","DOI":"10.1038\/s41598-019-47799-w","article-title":"The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy","volume":"9","author":"Endo","year":"2019","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.addr.2025.115671_b0940","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1021\/bm501166j","article-title":"In Situ Modulation of Dendritic Cells by Injectable Thermosensitive Hydrogels for Cancer Vaccines in mice","volume":"15","author":"Liu","year":"2014","journal-title":"Biomacromolecules"},{"issue":"4","key":"10.1016\/j.addr.2025.115671_b0945","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1021\/acs.nanolett.9b04094","article-title":"Synthetic Immunogenic Cell Death Mediated by Intracellular delivery of STING Agonist Nanoshells Enhances Anticancer Chemo-immunotherapy","volume":"20","author":"Chattopadhyay","year":"2020","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2025.115671_b0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119370","article-title":"Magnetic-responsive and targeted cancer nanotheranostics by PA\/MR bimodal imaging-guided photothermally triggered immunotherapy","volume":"219","author":"Guo","year":"2019","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0955","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1038\/s41598-019-41251-9","article-title":"RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy","volume":"9","author":"Yoo","year":"2019","journal-title":"Sci. Rep."},{"issue":"25","key":"10.1016\/j.addr.2025.115671_b0960","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.3748\/wjg.v29.i25.3984","article-title":"Impact of gut microbiome in the development and treatment of pancreatic cancer: Newer insights","volume":"29","author":"Bangolo","year":"2023","journal-title":"World J. Gastroenterol."},{"issue":"22","key":"10.1016\/j.addr.2025.115671_b0965","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12866-022-02465-6","article-title":"The impact of the human microbiome in tumorigenesis, cancer progression, and biotherapeutic development","volume":"12","author":"Doocey","year":"2022","journal-title":"BMC Microbiol."},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b0970","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1084\/jem.20180448","article-title":"The gut microbiome: Relationships with disease and opportunities for therapy","volume":"216","author":"Durack","year":"2019","journal-title":"J. Exp. Med."},{"issue":"6161","key":"10.1016\/j.addr.2025.115671_b0975","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.1240537","article-title":"The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide","volume":"342","author":"Viaud","year":"2013","journal-title":"Science"},{"issue":"6264","key":"10.1016\/j.addr.2025.115671_b0980","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"issue":"6264","key":"10.1016\/j.addr.2025.115671_b0985","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti\u2013PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"issue":"6371","key":"10.1016\/j.addr.2025.115671_b0990","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti\u2013PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"issue":"6371","key":"10.1016\/j.addr.2025.115671_b0995","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"24","key":"10.1016\/j.addr.2025.115671_b1000","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/jnci\/djt300","article-title":"Human Gut Microbiome and risk for Colorectal Cancer","volume":"105","author":"Ahn","year":"2013","journal-title":"JNCI J Natl Cancer Inst."},{"key":"10.1016\/j.addr.2025.115671_b1005","doi-asserted-by":"crossref","unstructured":"Goedert JJ, Jones G, Hua X, Xu X, Yu G, Flores R, et al. Investigation of the Association Between the Fecal Microbiota and Breast Cancer in Postmenopausal Women: a Population-Based Case-Control Pilot Study. JNCI J Natl Cancer Inst. 2015 Jun 1;107(8):djv147.","DOI":"10.1093\/jnci\/djv147"},{"issue":"56","key":"10.1016\/j.addr.2025.115671_b1010","doi-asserted-by":"crossref","first-page":"95176","DOI":"10.18632\/oncotarget.18820","article-title":"Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"},{"issue":"6371","key":"10.1016\/j.addr.2025.115671_b1015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"6529","key":"10.1016\/j.addr.2025.115671_b1020","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1126\/science.abf3363","article-title":"Fecal microbiota transplant overcomes resistance to anti\u2013PD-1 therapy in melanoma patients","volume":"371","author":"Davar","year":"2021","journal-title":"Science"},{"issue":"6529","key":"10.1016\/j.addr.2025.115671_b1025","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.addr.2025.115671_b1030","doi-asserted-by":"crossref","unstructured":"Lin Y, Xie M, Lau HCH, Zeng R, Zhang R, Wang L, et al. Effects of gut microbiota on immune checkpoint inhibitors in multi-cancer and as microbial biomarkers for predicting therapeutic response. Med. 2024 Nov;100530.","DOI":"10.1016\/j.medj.2024.10.007"},{"issue":"4","key":"10.1016\/j.addr.2025.115671_b1035","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1568812","article-title":"Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors","volume":"8","author":"Elkrief","year":"2019","journal-title":"Oncoimmunology"},{"issue":"23","key":"10.1016\/j.addr.2025.115671_b1040","doi-asserted-by":"crossref","first-page":"16512","DOI":"10.18632\/oncotarget.24751","article-title":"Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer","volume":"9","author":"Huemer","year":"2018","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.addr.2025.115671_b1045","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1665973","article-title":"Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients","volume":"8","author":"Huang","year":"2019","journal-title":"Oncoimmunology"},{"issue":"12","key":"10.1016\/j.addr.2025.115671_b1050","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of Prior Antibiotic Treatment with Survival and Response to Immune Checkpoint Inhibitor Therapy in patients with Cancer","volume":"5","author":"Pinato","year":"2019","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.addr.2025.115671_b1055","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.gastro.2016.11.018","article-title":"Fusobacterium nucleatum increases Proliferation of Colorectal Cancer Cells and Tumor Development in mice by Activating Toll-like Receptor 4 Signaling to Nuclear Factor\u2212\u03baB, and Up-regulating Expression of MicroRNA-21","volume":"152","author":"Yang","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.addr.2025.115671_b1060","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.cell.2017.07.008","article-title":"Fusobacterium nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy","volume":"170","author":"Yu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.addr.2025.115671_b1065","article-title":"Fusobacterium nucleatum reduces METTL3-mediated m6A modification and contributes to colorectal cancer metastasis","author":"Chen","year":"2022","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.addr.2025.115671_b1070","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.ccell.2024.08.019","article-title":"Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2025.115671_b1075","unstructured":"Michaud DS, Izard J, Wilhelm-Benartzi CS, You DH, Grote VA, Tj\u00f8nneland A, et al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut. 2013 Dec;62(12):10.1136\/gutjnl-2012\u2013303006."},{"issue":"4","key":"10.1016\/j.addr.2025.115671_b1080","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1158\/2159-8290.CD-17-1134","article-title":"The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune suppression","volume":"8","author":"Pushalkar","year":"2018","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b1085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/j.gastro.2018.04.001","article-title":"Gut Microbiota Promotes Tumor Growth in mice by Modulating Immune Response","volume":"155","author":"Sethi","year":"2018","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.addr.2025.115671_b1090","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ccr.2014.03.014","article-title":"Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia","volume":"25","author":"McAllister","year":"2014","journal-title":"Cancer Cell"},{"issue":"22","key":"10.1016\/j.addr.2025.115671_b1095","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1158\/0008-5472.CAN-15-0896","article-title":"IL-17 functions through the novel REG3\u03b2-JAK2-STAT3 inflammatory pathway to promote the transition from chronic pancreatitis to pancreatic cancer","volume":"75","author":"Loncle","year":"2015","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b1100","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1053\/j.gastro.2018.03.041","article-title":"Immune Cell production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells","volume":"155","author":"Zhang","year":"2018","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.addr.2025.115671_b1105","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190354","article-title":"Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer","volume":"217","author":"Zhang","year":"2020","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.addr.2025.115671_b1110","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.immuni.2016.02.007","article-title":"Intestinal interleukin-17 receptor signaling mediates reciprocal control of the gut microbiota and autoimmune inflammation","volume":"44","author":"Kumar","year":"2016","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b1115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ccell.2023.12.006","article-title":"Gut epithelial Interleukin-17 receptor a signaling can modulate distant tumors growth through microbial regulation","volume":"42","author":"Chandra","year":"2024","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.addr.2025.115671_b1120","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/carcin\/bgs112","article-title":"Periodontal disease, Porphyromonas gingivalis serum antibody levels and orodigestive cancer mortality","volume":"33","author":"Ahn","year":"2012","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b1125","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/pathogens14010002","article-title":"Intratumoral Fusobacterium nucleatum in Pancreatic Cancer: current and Future Perspectives","volume":"14","author":"D\u2019Antonio","year":"2025","journal-title":"Pathogens"},{"issue":"3\u20134","key":"10.1016\/j.addr.2025.115671_b1130","first-page":"125","article-title":"Periodontal Pathogens in the Etiology of Pancreatic Cancer","volume":"3","author":"\u00d6\u011frendik","year":"2017","journal-title":"Gastrointest Tumors."},{"issue":"12","key":"10.1016\/j.addr.2025.115671_b1135","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1136\/gutjnl-2018-317458","article-title":"Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer","volume":"68","author":"Gaiser","year":"2019","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.addr.2025.115671_b1140","doi-asserted-by":"crossref","first-page":"7209","DOI":"10.18632\/oncotarget.3109","article-title":"Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis","volume":"6","author":"Mitsuhashi","year":"2015","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.addr.2025.115671_b1145","doi-asserted-by":"crossref","first-page":"16801","DOI":"10.1038\/s41598-019-53041-4","article-title":"Fecal microbiome signatures of pancreatic cancer patients","volume":"14","author":"Half","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115671_b1150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1487242","article-title":"Succession of the multi-site microbiome along pancreatic ductal adenocarcinoma tumorigenesis","volume":"15","author":"Zhu","year":"2024","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.addr.2025.115671_b1155","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ibd.21830","article-title":"Differences of small intestinal bacteria populations in adults and children with\/without celiac disease: effect of age, gluten diet, and disease","volume":"18","author":"Nistal","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"issue":"6356","key":"10.1016\/j.addr.2025.115671_b1160","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1126\/science.aah5043","article-title":"Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine","volume":"357","author":"Geller","year":"2017","journal-title":"Science"},{"issue":"7777","key":"10.1016\/j.addr.2025.115671_b1165","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41586-019-1608-2","article-title":"The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL","volume":"574","author":"Aykut","year":"2019","journal-title":"Nature"},{"issue":"39","key":"10.1016\/j.addr.2025.115671_b1170","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000022250","article-title":"Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer","volume":"99","author":"Nakano","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.addr.2025.115671_b1175","doi-asserted-by":"crossref","first-page":"7953","DOI":"10.2147\/CMAR.S215697","article-title":"Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective study","volume":"11","author":"Imai","year":"2019","journal-title":"Cancer Manag. Res."},{"issue":"15","key":"10.1016\/j.addr.2025.115671_b1180","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1002\/cam4.3870","article-title":"Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients","volume":"10","author":"Mohindroo","year":"2021","journal-title":"Cancer Med."},{"issue":"12","key":"10.1016\/j.addr.2025.115671_b1185","article-title":"Evolved bacterial resistance to the chemotherapy gemcitabine modulates its efficacy in co-cultured cancer cells","volume":"3","author":"Sayin","year":"2023","journal-title":"Elife"},{"issue":"7950","key":"10.1016\/j.addr.2025.115671_b1190","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41586-023-05728-y","article-title":"Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer","volume":"615","author":"Tintelnot","year":"2023","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.addr.2025.115671_b1195","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1158\/1078-0432.CCR-14-2600","article-title":"Very long-term survival following resection for pancreatic cancer is not explained by commonly mutated genes: results of whole-exome sequencing analysis","volume":"21","author":"Molin","year":"2015","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res."},{"issue":"4","key":"10.1016\/j.addr.2025.115671_b1200","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.cell.2019.07.008","article-title":"Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes","volume":"178","author":"Riquelme","year":"2019","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.addr.2025.115671_b1205","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3390\/cells14050361","article-title":"Inflammatory Stimuli and Fecal Microbiota Transplantation Accelerate Pancreatic Carcinogenesis in Transgenic mice, Accompanied by changes in the Microbiota Composition","volume":"14","author":"\u015awidnicka-Siergiejko","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.addr.2025.115671_b1210","doi-asserted-by":"crossref","unstructured":"Goedert JJ, Jones G, Hua X, Xu X, Yu G, Flores R, et al. Investigation of the Association Between the Fecal Microbiota and Breast Cancer in Postmenopausal Women: a Population-Based Case-Control Pilot Study. JNCI J Natl Cancer Inst. 2015 Jun 1;107(8):djv147.","DOI":"10.1093\/jnci\/djv147"},{"key":"10.1016\/j.addr.2025.115671_b1215","doi-asserted-by":"crossref","unstructured":"Decker-Farrell AR, Sastra SA, Harimoto T, Hasselluhn MC, Palermo CF, Ballister ER, et al. Tumor-selective treatment of metastatic pancreatic cancer with an engineered, probiotic living drug. BioRxiv Prepr Serv Biol. 2024 May 5;2024.05.02.592216.","DOI":"10.1101\/2024.05.02.592216"},{"issue":"2","key":"10.1016\/j.addr.2025.115671_b1220","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ymthe.2021.08.023","article-title":"Targeting of pancreatic cancer cells and stromal cells using engineered oncolytic Salmonella typhimurium","volume":"30","author":"Tan","year":"2022","journal-title":"Mol Ther J Am Soc Gene Ther."},{"issue":"13","key":"10.1016\/j.addr.2025.115671_b1225","doi-asserted-by":"crossref","first-page":"20729","DOI":"10.18632\/oncotarget.15117","article-title":"32-Phosphorus selectively delivered by listeria to pancreatic cancer demonstrates a strong therapeutic effect","volume":"8","author":"Chandra","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b1230","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s41392-024-01973-3","article-title":"Aptamer-drug conjugates-loaded bacteria for pancreatic cancer synergistic therapy","volume":"9","author":"Xiao","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"31","key":"10.1016\/j.addr.2025.115671_b1235","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202401905","article-title":"Nanobody-Engineered Biohybrid Bacteria Targeting Gastrointestinal Cancers Induce Robust STING-Mediated Anti-Tumor Immunity","volume":"11","author":"Xu","year":"2024","journal-title":"Adv. Sci."},{"issue":"3","key":"10.1016\/j.addr.2025.115671_b1240","article-title":"Harnessing the Engineered Probiotic-Nanosystem to Remodulate Tumor Extracellular Matrix and Regulate Tumor-Colonizing Bacteria for improving Pancreatic Cancer Chemo-Immunotherapy","volume":"21","author":"Yao","year":"2025","journal-title":"Small Weinh Bergstr Ger."},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b1245","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1038\/s41467-024-51534-z","article-title":"Probiotics functionalized with a gallium-polyphenol network modulate the intratumor microbiota and promote anti-tumor immune responses in pancreatic cancer","volume":"15","author":"Han","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.addr.2025.115671_b1250","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1038\/s41598-025-94183-y","article-title":"Machine learning models for pancreatic cancer diagnosis based on microbiome markers from serum extracellular vesicles","volume":"15","author":"Lee","year":"2025","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.addr.2025.115671_b1255","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3390\/biomedicines13041000","article-title":"Metagenomic Microbial Signatures for Noninvasive Detection of Pancreatic Cancer","volume":"13","author":"Chen","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.addr.2025.115671_b1260","doi-asserted-by":"crossref","unstructured":"Zhang Y, Zhang H, Liu B, Ning K. Highly accurate diagnosis of pancreatic cancer by integrative modeling using gut microbiome and exposome data. iScience. 2024 Feb 21;27(3):109294.","DOI":"10.1016\/j.isci.2024.109294"},{"key":"10.1016\/j.addr.2025.115671_b1265","doi-asserted-by":"crossref","unstructured":"Villani A, Fontana A, Panebianco C, Ferro C, Copetti M, Pavlovic R, et al. A powerful machine learning approach to identify interactions of differentially abundant gut microbial subsets in patients with metastatic and non-metastatic pancreatic cancer. Gut Microbes. 16(1):2375483.","DOI":"10.1080\/19490976.2024.2375483"},{"key":"10.1016\/j.addr.2025.115671_b1270","first-page":"13","article-title":"A multi-omics machine learning framework in predicting the recurrence and metastasis of patients with pancreatic adenocarcinoma","volume":"3","author":"Li","year":"2022","journal-title":"Front. Microbiol."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25001565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25001565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T05:04:09Z","timestamp":1779771849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X25001565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":254,"alternative-id":["S0169409X25001565"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2025.115671","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Classic versus innovative strategies for immuno-therapy in pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2025.115671","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115671"}}